Skip to content

AHC International Media Library

Alternating Hemplegia of Childhood and ATP1A3 disorders

  • Interviews
  • Home Videos
  • News
  • Associations
  • Documentaries
  • Presentations
  • Contact
  • About AHCIM
  • Articles
  • Toggle search form

Dr Steven Gray talks about AAV gene therapy that can potentially help AHC patients.

Posted on November 4, 2018 By siggi


Dr. Steven Gray is one of the world leaders in developing gene therapies for rare and ultra-rare diseases. He works at the University of Texas Southwestern, where he is currently an Associate Professor in the Department of Pediatrics at the University of Texas Southwestern Medical Center.

Interviews Tags:aav, agusta fanney, AHC, ahcim, gene therapy, siggi johannesson, steven gray

Post navigation

Previous Post: Lynn Egan – Together we are strong
Next Post: Simon Frost at the ATP1A3 Symposium in Disease – Chicago 2018

Related Posts

Behind the Episode, an AHC advocacy podcast Associations
Kenneth Silver – Why do not all AHC Patients have the ATP1A3 mutation? 2/3 Interviews
Richard D´Alli Pschycologist at Duke University Interviews
Arn M.J.M van den Maagdenberg – London 2016 Interviews
Hope for Anabel Documentaries
Sona Nevsimalova – Lunteren 2014 Interviews

Copyright © 2026 AHC International Media Library.

Powered by PressBook Masonry Dark